(RTTNews) - AbbVie (ABBV) reported positive results from the Phase 2 APEX Part B study of zumilokibart, in adults with moderate to severe atopic dermatitis. All three dose regimens met the study's primary endpoint, demonstrating significantly greater EASI-75 response rates compared with placebo at Week 16. Zumilokibart is a half-life extended monoclonal antibody targeting IL-13 and is being developed as a potential treatment for atopic dermatitis. According to the company, the mid-dose regimen was selected for Phase 3 development based on its efficacy, safety and dosing profile. The data are being presented as a late breaker at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.